471 related articles for article (PubMed ID: 19954478)
1. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.
Yamagishi S
Ther Apher Dial; 2009 Dec; 13(6):534-9. PubMed ID: 19954478
[TBL] [Abstract][Full Text] [Related]
2. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
Yamagishi S
Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
[TBL] [Abstract][Full Text] [Related]
3. A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H
Med Hypotheses; 2007; 69(2):338-40. PubMed ID: 17329034
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Inoue H
Med Hypotheses; 2005; 65(5):953-5. PubMed ID: 15996828
[TBL] [Abstract][Full Text] [Related]
5. Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(2):392-4. PubMed ID: 15922119
[TBL] [Abstract][Full Text] [Related]
6. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
7. Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury.
Soulis T; Thallas V; Youssef S; Gilbert RE; McWilliam BG; Murray-McIntosh RP; Cooper ME
Diabetologia; 1997 Jun; 40(6):619-28. PubMed ID: 9222639
[TBL] [Abstract][Full Text] [Related]
8. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
Yamagishi S; Takeuchi M; Inagaki Y; Nakamura K; Imaizumi T
Int J Clin Pharmacol Res; 2003; 23(4):129-34. PubMed ID: 15224502
[TBL] [Abstract][Full Text] [Related]
9. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.
Yamagishi S; Maeda S; Matsui T; Ueda S; Fukami K; Okuda S
Biochim Biophys Acta; 2012 May; 1820(5):663-71. PubMed ID: 21440603
[TBL] [Abstract][Full Text] [Related]
10. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
Yamagishi S; Ueda S; Okuda S
Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
[TBL] [Abstract][Full Text] [Related]
11. Potential clinical utility of advanced glycation end product cross-link breakers in age- and diabetes-associated disorders.
Yamagishi S
Rejuvenation Res; 2012 Dec; 15(6):564-72. PubMed ID: 22950433
[TBL] [Abstract][Full Text] [Related]
12. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.
Park L; Raman KG; Lee KJ; Lu Y; Ferran LJ; Chow WS; Stern D; Schmidt AM
Nat Med; 1998 Sep; 4(9):1025-31. PubMed ID: 9734395
[TBL] [Abstract][Full Text] [Related]
13. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes.
Rojas A; Morales MA
Life Sci; 2004 Dec; 76(7):715-30. PubMed ID: 15581904
[TBL] [Abstract][Full Text] [Related]
14. RAGE biology, atherosclerosis and diabetes.
Barlovic DP; Soro-Paavonen A; Jandeleit-Dahm KA
Clin Sci (Lond); 2011 Jul; 121(2):43-55. PubMed ID: 21457145
[TBL] [Abstract][Full Text] [Related]
15. AGE, RAGE, and ROS in diabetic nephropathy.
Tan AL; Forbes JM; Cooper ME
Semin Nephrol; 2007 Mar; 27(2):130-43. PubMed ID: 17418682
[TBL] [Abstract][Full Text] [Related]
16. Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent?
Kanková K
Proc Nutr Soc; 2008 Feb; 67(1):60-74. PubMed ID: 18234133
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications.
Yan SF; Ramasamy R; Schmidt AM
Nat Clin Pract Endocrinol Metab; 2008 May; 4(5):285-93. PubMed ID: 18332897
[TBL] [Abstract][Full Text] [Related]
18. The AGE/RAGE axis in diabetes-accelerated atherosclerosis.
Jandeleit-Dahm K; Watson A; Soro-Paavonen A
Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):329-34. PubMed ID: 18290873
[TBL] [Abstract][Full Text] [Related]
19. Role of advanced glycation end product (AGE)-induced receptor (RAGE) expression in diabetic vascular complications.
Chawla D; Bansal S; Banerjee BD; Madhu SV; Kalra OP; Tripathi AK
Microvasc Res; 2014 Sep; 95():1-6. PubMed ID: 24984291
[TBL] [Abstract][Full Text] [Related]
20. Advanced glycation end products: sparking the development of diabetic vascular injury.
Goldin A; Beckman JA; Schmidt AM; Creager MA
Circulation; 2006 Aug; 114(6):597-605. PubMed ID: 16894049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]